Dr. Reddy’s Lab launches India’s first DCGI-approved Semaglutide injection for Type 2 Diabetes

Dr. Reddy’s Laboratories on Saturday launched Obeda, a semaglutide injection for Type 2 diabetes, becoming the first Indian company to receive approval from the Drugs Controller General of India (DCGI) for a generic version of the drug.

The launch marks its entry into the GLP-1 receptor agonist therapy segment from day one of patent expiry, the company said in a regulatory filing.

Obeda is available in 2 mg and 4 mg strengths in a pre-filled disposable pen for once-a-week subcutaneous administration. Each pen delivers a minimum of four weekly doses, with the therapy priced at Rs 4,200 per month for both strengths.


Also read: Semaglutide patent expiry: India’s next big public health inflection point

In a Phase III study involving 312 participants, the drug demonstrated non-inferior efficacy and a safety profile comparable to the innovator drug, with similar outcomes in glycaemic control and related measures.

The company said development and manufacturing of the drug, including the active pharmaceutical ingredient and formulation, were carried out in-house.

Dr. Reddy’s added it plans to introduce generic semaglutide in multiple countries, subject to regulatory approvals.

"Today’s launch marks a significant step in our commitment to expand our portfolio in critical therapeutic areas with differentiated solutions to patients in India and across global markets. Our foray into GLP-1 therapies reflects our capabilities in complex product development and peptide science," Erez Israeli, Chief Executive Officer of Dr. Reddy’s, said.

"As part of phase-1 launch, we aim to introduce generic semaglutide in several countries and, through our ‘One Product, One Quality’ approach, we are committed to ensure the same high‑quality product across all markets, Israeli added.